An open, crossover and randomized study was carried out to compare the safety and efficacy of salbutamol inhaled using the dry-powder inhaler Turbuhalers, and using a pressurized metered-dose inhaler (pMD1). Twelve patients with moderate to severe asthma, aged 47-68 years, were included in the study. On two separate days, patients received a total dose of 16OOpg of salbutamol administered in a cumulative dose fashion: 100, 100, 200, 400 and SOOpg at 3-min intervals.
Introduction
Inhaled short-acting &-agonists have played an important role in the management of asthma for more than two decades. Their immediate bronchodilating effect makes them the medication of choice for treatment of acute asthma attacks and for pre-treatment of exercise-and allergen-induced bronchoconstriction (1) . Salbutamol, a relatively selective j&-agonist (2) is well established in the treatment of reversible obstructive airway diseases. The predominantly used formulation of inhaled salbutamol has been the chlorofluorocarbon (CFC)-propelled pressurized metered-dose inhaler (pMD1). Turbuhaler K: (Astra Draco), an inspiratory-flow-driven, multidose, dry-powder inhaler delivers micronized drug without the need of propellants (3) . When using Turbuhaler, patients do not need to co-ordinate dose acutation with inhalation of the drug; a problem which is commonly associated with the use of pMDIs and which may influence patient compliance and drug efficacy (4, 5) . A previous study showed that Turbuhaler delivers about twice the amount of terbutaline, another short-acting &agonist, to the lungs as the corresponding pMD1, and that the observed difference in deposition is reflected in the bronchodilating effect of terbutaline (6) .
In general, &agonists are well tolerated and have sufficient safety margins even at high doses. However, at doses higher than 50O,~g, inhaled salbutamol has been shown to cause extrapulmonary effects, such as changes in blood pressure, increased heart rate, tremor and hypokalaemia (7).
The aim of this study was to determine the relative dose potency, with regard to safety and efficacy, of the new drug formulation, salbutamol Turbuhaler, vs salbutamol pMD1 in patients with asthma.
Patients
and Methods
PATIENTS
Twelve outpatients (three women) with reversible airways obstruction were included in the study (Table 1) . They had Patients were not included if they had a theophylline serum level >28 pm011 -i. Hospitalization for treatment of airway disease within 1 month or significant disorders other than airway disease also disqualified patients from inclusion in the study, as did pregnancy, breast-feeding or active planning of pregnancy. Concomitant &-agonist medication was withheld as follows: inhaled short-acting, 8 h; inhaled long-acting, 24 h; and oral, nebulized or parenteral, 36 h prior to and throughout the study. Oral steroids were not to be used within 30 days prior to enrolment, and patients using orally or nasally inhaled steroids were to keep the dose constant 30 days prior to and throughout the study. The patients were allowed to use salbutamol pMD1 as rescue medication at any time during the study, except within 8 h prior to the baseline spirometry at the enrolment visit and on the two study days.
The study was performed in accordance with the principles stated in the Declaration of Helsinki and the principles of Good Clinical Practice adopted by the European Community. It was approved by the Swedish Medical Products Agency and the Ethics Committee at the University of Gothenburg. The patients gave their signed informed consent before they were enrolled in the study.
STUDY DESIGN
The study was of an open, crossover and randomized design. Patients received cumulative doses of salbutamol: 100, 100, 200, 400 and 8OOpg at 30-min intervals, using Turbuhaler (Astra Draco) or pMD1 (Glaxo), on two study days separated by at least 24 h. Inspiratory flow through Turbuhaler and pMD1 was measured by connecting the inhalers one at a time in a serial mode to a Vitalograph MD1 modified Compact spirometer (Vitalograph Ltd, U.K.). Patients inhaled salbutamol while in a sitting, upright position. When using Turbuhaler, they were instructed to inhale deeply and forcefully. When using pMD1, they were instructed to inhale as slowly as possible and to actuate the dose at the beginning of the full inhalation. After completed drug inhalation, the patients were asked to hold their breath for 10 s. Patients practised the inhalation manoeuvres at the enrolment visit using empty Turbuhaler inhalers and placebo pMDIs.
Baseline measurements were made within 30 min before the first study drug administration on each study day. Blood pressure was then measured at 15 min after each dose using a standard sphygmomanometer. Readings were taken with the patient in the sitting position after a 5-min rest. Heart rate was measured over consecutive 5-min intervals between 10 and 30 min after each dose in a continuous three-lead electrocardiogram (Marquette Series 8500 Holter recording). The QT interval was measured at 15 and 25 min after each dose in five consecutive QRS complexes using a Siemens Elema Mingograf. The QT interval was corrected for heart rate (QTc) according to Bazett (8). Subjective tremor was estimated on a four-point scale (O=no tremor; 1 =just perceivable; 2=perceivable; 3 =troublesome;) at 20 min after each dose, followed by an objective tremor measurement using a one-plane accelerometer applied to the patient's right-hand middle finger (9). During the measurement, the patient's wrist rested on the table and the finger was held moderately stretched. Acceleration in the up-down direction was measured during 5 x 10 s using an accelerometer connected to an analogue pre-amplifier (Anglo Devices), a Macintosh II computer with an A/D-converter board NB-MI016L (National Instruments) and the software package LabVIEW (National Instruments). The accelerometer signal was analysed by Fast Fourier Transformation to achieve the frequency spectrum.
The spectrum was integrated in 20 intervals of 2.5 Hz each with a sampling speed of 100 Hz. Tremor was then calculated by totalling the integrals for 2.5-12.5 Hz, i.e. the range of maximum amplitude demonstrated previously for physiological tremor and tremor induced by intravenous terbutaline in healthy volunteers (unpubl. obs.), and by dividing the sum by 1000. Tremor was expressed as tremor units calculated as the sum of these integrated values. For determination of serum potassium concentration, venous blood was collected at 23 min after each dose. Serum was analysed using an ion-selective electrode method (10,ll) and the COBAS MIRA S instrument (Roche Diagnostics, Switzerland) fitted with an ion exchange module. Lung function variables, FEV, and forced vital capacity (FVC), were measured at 25 min after each dose and, in accordance with recommendations by the American Thoracic Society (12), were measured using a Vitalography Compact spirometer (Vitalograph Ltd, U.K.). Adverse events were assessed by means of a standard question addressed to the patients at 60 min after the last dose on each study day, in the morning following each of the two study days and at the follow-up visit.
STATISTICAL METHODS
The change from baseline for each patient and treatment was calculated for blood pressure, heart rate and QTc. Analysis of variance (ANOVA) was used to determine whether there was any difference in mean response between the two inhalers. A probability level of less than 5% was considered significant. Tremor, serum potassium and lung function variables (FEV, and FVC) were analysed under the following model: mean effect = patient +inhaler + period+ln(dose). When possible, period adjusted means were approximated with straight, parallel lines and scaled to percentage increase from the mean baseline on the two study days. The relative dose potency factor was estimated as eD", where D is the estimated difference between the inhalers (the horizontal distance between the parallel lines) and b is the coefficient of the regression parameter ln(dose). A 95% confidence interval for the relative dose potency factor was computed using Fieller's method (13). A relative dose potency factor of 1.0 means that there is no difference between the two inhalers.
Results
Peak inspiratory flow was, on average, 64 1 min ~ ' (range: 5472) when using Turbuhaler and 40 1 min -' (range: 26-54) when using the pMD1. Mean inhalation volume ranged between 1.8 and 4.8 1 when using Turbuhaler and between 1.1 and 5.0 1 when using pMD1. Breath-holding was longer than 5 s in all cases except one (2.5 s). There was no difference between the two study days with regard to baseline values of extrapulmonary variables recorded prior to study drug administration (Table 2) .
CARDIOVASCULAR EFFECTS
Systolic and diastolic blood pressures remained unchanged after inhalation of salbutamol via Turbuhaler or pMD1, even at the highest dose level. Salbutamol inhaled via Turbuhaler caused a larger increase in heart rate than did salbutamol inhaled via pMD1 (P<O.OOOl). Maximum heart rate was reached between 25 and 30 min after the last dose on each study day. Mean of the maximum values recorded within this interval was 95 beats min -' (range: 78-109) for Turbuhaler and 89 beats min -i (range: 76-106) for pMD1. Salbutamol slightly lengthened the QTc interval. Although small, the effect was more pronounced with Turbuhaler, than with pMD1 (P<O.OOl). Assuming parallel profiles, the difference between the inhalers was estimated to 11 ms with a 95% confidence interval of 5-16 ms. Individual QTc intervals were considered normal, i.e. less than 430 ms for men and less than 450 ms for women (14), at all dose levels except in one case (a prolonged QTc interval of 460ms, followed by a normal QTc interval of 420 ms, was observed for one male patient after cumulative doses of 800 and 1600 ,ug, respectively, inhaled via Turbuhaler). Cumulative doses of 800 and 1600,~~g inhaled via Turbuhaler caused tremor in the other three patients, two of whom reported tremor also after 1600~8 inhaled via pMD1. Tremor was scored 1 (just perceivable) in all cases. The increase in objectively measured tremor was larger with Turbuhaler than with pMD1 (P<O.OOOl) (Fig. 1) . Based on the three highest doses, the relative dose potency of Turbuhaler vs pMD1 was estimated to 2.3 with a 95% confidence interval of 1.54.4.
SERUM POTASSIUM
Serum potassium concentration increased after the first one to two doses of salbutamol and then declined by additional doses inhaled via Turbuhaler or pMD1 (Fig. 2) . Based on the three highest doses, the relative dose potency of Turbuhaler rs pMDE was estimated to 2.0 with a 95% confidence interval of 1.3-3.6. The lowest serum potassium concentration value for an individual patient was 3.7 mmol 1 -' recorded after the highest cumulative dose (1600 pug) inhaled via Turbuhaler.
ADVERSE EVENTS
There were no reports of adverse events. There were no findings of clinical relevance on physical examination or in the clinical chemistry and haematology tests performed during or after the completion of the study.
SRiROMETRY
Baseline FEV, (mean & SD) was similar on the two study days (1.43 * 0.45 1 and 1.43 f 0.48 1). Individual changes from the first to the second study day varied from a reduction of 10.5% to an increase of 7.3%, indicating that the patients' asthma was fairly stable throughout the study. After inhalation of salbutamol, FEV, increased successively up to 2.04 1 (Turbuhaler) and 1.92 1 (pMD1) after inhalation of a cumulative dose of 16OOpg (Fig. 3) . Based on the horizontal distance between the parallel lines in Fig. 4 , the relative dose potency of Turbuhaler vs pMD1 with regard to FEV, was estimated to 3.0 with a 95% confidence interval of 1.8-5.8. When based on FVC, the relative dose potency was estimated to 4.1 with a 95% confidence interval of 2.2-10.0.
Discussion
This investigation was performed to compare the safety and efficacy of a new formulation, salbutamol Turbuhaler, with that of a conventional pMD1 formulation containing the same active drug substance. When comparing different inhalers, it is preferable to use a double-blind and doubledummy technique. However, considering the number of inhalations taken at each dosing, especially at the higher dose levels, this was not feasible in the present study. Not only would it have increased the effort required by the patients, but it would also have considerably prolonged the time between inhalations and assessments.
The results of this study showed changes in extrapulmonary and bronchodilating responses to salbutamol inhaled Turbuhaler or pMD1. Serum potassium concentration was chosen as the primary safety variable because of its sensitivity and reproducibility (6) . The hypokalaemic effect of salbutamol inhaled via Turbuhaler was found to correspond to that produced by twice the dose inhaled via pMD1. It was noticed, however, that the serum potassium concentration remained above the lower limit of the reference range (3.5-5.0 mm011 -') even after a cumulative dose of 16OOpg using either inhaler, and that it was not associated with any symptoms of clinical relevance. Salbutamol inhaled via Turbuhaler caused a larger increase in heart rate, QTc interval and tremor than did equal doses of salbutamol inhaled via pMD1. The magnitude by which these variables were affected was small and considered to have no implications for normal, clinical use of salbutamol.
Salbutamol inhaled via Turbuhaler produced a significantly greater bronchodilation than did equal doses of salbutamol inhaled via pMD1. The relative dose potency of salbutamol Turbuhaler vs salbutamol pMD1 was 3.0. This means that a Turbuhaler inhaler, on average, should contain about one-third of the nominal dose of pMD1 for the same bronchodilating effect to be achieved. This is in line with a recent single-dose study showing that the same bronchodilating effect produced by salbutamol inhaled via pMD1 can be obtained by half the dose inhaled via Turbuhaler (15) . Despite the high cumulative dose of 16OOpg of salbutamol in the present study, a maximum bronchodilating effect was not reached with either of the two inhalers. This absence of a dose-response plateau is consistent with results of several other &-agonists studies using cumulative dosing regimens (16, 17) . The mechanism behind the finding is assumed to be bronchodilation of airways after the initial doses with a cumulative technique SALBUTAMOLTURBUHALER" CUMULATIVEDOSE 329 allowing increased penetration of succeeding doses. Since the first dose was inhaled at 8.30 a.m. and the last FEV, was measured at 11 a.m., it cannot be precluded that natural elevation of FEV, due to the circadian rhythm (18) may also have contributed to the increased bronchodilation with sequential doses. The higher potency of salbutamol Turbuhaler in producing extrapulmonary and bronchodilating effects was probably a result of a higher lung deposition, as the latter causes an increased concentration of active drug not only in the airways, but also in the systemic circulation (6) . The beneficial effect of inhaled salbutamol seemed to outweigh the adverse effects when Turbuhaler was used instead of pMD1, as indicated by the relative dose potencies for salbutamol Turbuhaler vs salbutamol pMD1 of 3.0 and 4.1 for FEV, and FVC, respectively, and 2.3 and 2.0 for tremor and serum potassium, respectively. From this, it follows that, within the dose range studied, salbutamol inhaled via Turbuhaler had an equal or better therapeutic ratio than salbutamol inhaled via pMD1.
In conclusion, salbutamol Turbuhaler was found to be more potent than salbutamol pMD1 with regard to extrapulmonary effects in patients with moderate to severe asthma. The potency difference was numerically even more pronounced when considering the bronchodilating effect, suggesting that salbutamol Turbuhaler had a better therapeutic ratio than salbutamol pMD1. Neither inhaler caused any clinically significant adverse effects at cumulative doses of salbutamol up to 16OOpg.
